UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 78

of 'Induction therapy for acute myeloid leukemia in younger adults'

78
TI
Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts.
AU
Kondo T, Tasaka T, Sano F, Matsuda K, Kubo Y, Matsuhashi Y, Nakanishi H, Sadahira Y, Wada H, Sugihara T, Tohyama K
SO
Leuk Res. 2009;33(9):e137. Epub 2009 Apr 16.
 
We studied the efficacy and pharmacokinetics of imatinib mesylate (IM) and bcr-abl expression in a Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) patient, a rare disease with a poor prognosis. Although sufficient IM trough concentrations were maintained, bcr-abl transcripts revealed only one-log reduction with IM monotherapy, suggesting a resistance against IM, and this patient required additional chemotherapy. Despite the resistance against IM at induction therapy, the patient has been in complete molecular response for more than 6 months with IM maintenance monotherapy. Our experience suggests that IM might have a positive role in consolidation and/or maintenance therapy in remission Ph + AML patients.
AD
Division of Hematology Department of Medicine, Kawasaki Medical School, Okayama 701-0192, Japan.
PMID